Department of Gastroenterology, Ruian People's Hospital, Ruian, Wenzhou, Zhejiang, China (mainland).
Department of Pathology, Ruian People's Hospital, Ruian, Wenzhou, Zhejiang, China (mainland).
Med Sci Monit. 2017 Dec 21;23:6033-6041. doi: 10.12659/msm.905314.
BACKGROUND High expression of the RNA-binding motif protein 3 (RBM3) has previously been described as a favorable clinicopathological factor in several cancers, including ovarian cancer, colorectal cancer, prostate cancer, and breast cancer. The aim of this study was to examine the prognostic implications of RBM3 expression in gastric cancer. MATERIAL AND METHODS Immunohistochemical analysis of RBM3 expression from 123 patients showed that upregulated RBM3 was mainly found in intestinal-type (n=78, case=59) cancer compared to diffuse-type (n=15, case=8) and mixed-type (n=30, case=17). There were no significant differences in RBM3 expression in subgroups of clinicopathological parameters. RBM3 expression was strongly associated with p53 but not with Ki-67. Cox univariate analysis revealed that high RBM3 expression was closely associated with prolonged overall survival time (HR 0.504, 95% CI: 0.300-0.845, P=0.009). Multivariate analysis remained supporting these associations when adjusted for age, sex, tumor size, differentiation grade, TNM stage, lymphatic invasion, and Ki-67 and p53 expression (HR 0.541, 95% CI: 0.308-0.952, P=0.033), where Lauren grade was not included. Lauren grade was the only factor with independent prognostic significance in a model adjusted for all factors. These results were confirmed by Kaplan-Meier analysis. RESULTS Therefore, together with the upregulated RBM3 expression observed in intestinal-type of Lauren grade, we suggest that upregulation of RBM3 is partially responsible for the favorable overall survival in cases with intestinal Lauren grade, which is demonstrated by the box diagram and Kaplan-Meier analysis. Our results showed that high RBM3 expression in gastric cancer is mainly found in intestinal-type of Lauren grade and is associated with longer overall survival time. CONCLUSIONS We found that RBM3 is a potential biomarker of good prognosis and deserves further validation.
RNA 结合基序蛋白 3（RBM3）的高表达先前已被描述为几种癌症（包括卵巢癌、结直肠癌、前列腺癌和乳腺癌）的有利临床病理因素。本研究旨在探讨 RBM3 在胃癌中的预后意义。
对 123 例患者的 RBM3 表达进行免疫组织化学分析表明，与弥漫型（n=15，病例=8）和混合型（n=30，病例=17）相比，上调的 RBM3 主要存在于肠型（n=78，病例=59）癌症中。RBM3 表达在临床病理参数亚组中无显著差异。RBM3 表达与 p53 强烈相关，但与 Ki-67 无关。Cox 单因素分析显示，高 RBM3 表达与总生存时间延长密切相关（HR 0.504，95%CI：0.300-0.845，P=0.009）。当调整年龄、性别、肿瘤大小、分化程度、TNM 分期、淋巴浸润、Ki-67 和 p53 表达时，多因素分析仍然支持这些关联（HR 0.541，95%CI：0.308-0.952，P=0.033），其中不包括 Lauren 分级。在调整所有因素的模型中，Lauren 分级是唯一具有独立预后意义的因素。这些结果通过 Kaplan-Meier 分析得到了证实。
因此，结合 Lauren 分级肠型中上调的 RBM3 表达，我们认为 RBM3 的上调部分解释了 Lauren 分级肠型病例中良好的总体生存率，这通过箱线图和 Kaplan-Meier 分析得到了证实。我们的结果表明，胃癌中高 RBM3 表达主要存在于 Lauren 分级肠型中，与总生存时间延长相关。
我们发现 RBM3 是一种潜在的预后良好的生物标志物，值得进一步验证。
